Ampalex

Research use only, not for human use.

Ampalex (Ampakine CX516; CX516; BDP 12) is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator as a treatment for Alzheimer's disease.

Ampalex (Ampakine CX516; CX516; BDP 12) is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator as a treatment for Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI).(In Vitro):.(In Vivo):The specific extradimensional deficits produced by sub-chronic or early postnatal postnatal phencyclidine treatment were significantly attenuated by CX516 (10, and 20 mg/kg, s.c.).

——

The specific extradimensional deficits produced by sub-chronic or early postnatal postnatal phencyclidine treatment were significantly attenuated by CX516 (10, and 20 mg/kg, s.c.). Animal Model:Male Lister Hooded rats (56-63 postnatal day)Dosage:5, 10, 20, and 40 mg/kg Administration:Subcutaneously Result:Two doses (10 and 20 mg/kg) were highly significant in improving the extradimensional shift deficit induced by either treatment regimes. Two doses (5 and 40 mg/kg) was ineffective at reversing the extradimensional impairment induced by the sub-chronic postnatal phencyclidine treatment regime.

Ampalex | BDP-12 | Benzoyl-Piperidine-12

Neuroscience

GluR

AMPA

Neurological Disease

——

154235-83-3

241.29

C14H15N3O

>98% (HPLC)

DMSO: 40 mg/mL

O=C(N1CCCCC1)C2=CC=C3N=CC=NC3=C2

1-(quinoxalin-6-ylcarbonyl)piperidine

(-20℃)

With Ice Pack

≥ 2 years